Mission

We are a full service, global pharmaceutical CRO lab that provides high quality service to our clients and provides opportunities for our employees in grow a career in a healthy work environment.

Vision

To become one of the best CROs in the world by providing the best service possible, using the best technical know-how at a reasonable value, to enable our clients to develop life-saving medications.

Values

Quality We are committed to excellence in the results we achieve, and how we achieve them.

Integrity Being honest, reliable and accountable in our words and behavior, doing the right things for our clients, company, community, and ourselves.

Respect for people. Promote a diverse culture and commitment to mutually respect our teammates, our customers, and people around us.

Collaboration Working together to achieve common goals is the foundation of our success; seek input and listen, and be flexible and responsive.

Song Li, Ph.D.

Song Li, Ph.D.

Chairman, Frontage Holdings
Song Li, Ph.D.

Song Li, Ph.D.

Chairman, Frontage Holdings

Dr. Song Li founded Frontage Laboratories in 2001 with the ambition of building a client-focused organization to help solve the most complex drug development challenges. Prior to Frontage, Dr. Li held management positions at Great Valley Pharmaceuticals and Wyeth. During this time, he led numerous projects related to the development of pharmaceutical products.

Dr. Li has authored more than 15 scientific publications spanning a wide range of topics, including chiral separations, drug-protein interactions, pharmacokinetics, and analytical chemistry. Importantly, Dr. Li has been the recipient of numerous awards, most recently Healthcare CEO award from Philadelphia Alliance for Capital and Technologies, Ernst & Young Entrepreneur of the Year Award,  the “Realizing the American Dream” award from the Pennsylvania Welcoming Society, and the Outstanding 50 Asian Americans in Business Award from the AABDC.

Dr. Li earned a doctor of philosophy degree in analytical chemistry from McGill University and a bachelor of science degree in chemistry from Zhengzhou University in China.

 

linkedin logo 150x150 - Song Li, Ph.D.

 

Read Full Bio
Shierly Xu

Shierly Xu

General Manager, Frontage Laboratories China
Shierly Xu

Shierly Xu

General Manager, Frontage Laboratories China

General Manager, Frontage Laboratories China. Responsible for business development, and overall operations across Frontage China.

Graduated from the Pharmacy department of Shanghai Medical University (now Fudan University Shanghai Medical College); Accumulated over 14 years of professional experience in sales, marketing, and medical departments within multinational pharmaceutical corporations including Amgen, Roche Pharma & Roche Diagnostics, and GlaxoSmithKline (GSK), demonstrating extensive expertise in pharmaceutical commercial operations. Joined Tigermed Group in 2011 and founded Teddy Clinical Research Laboratory, a clinical research organization specializing in central laboratory services.

Read Full Bio
Raymond Yan

Raymond Yan

Senior Vice President, Frontage Laboratories China, with overall management
Raymond Yan

Raymond Yan

Senior Vice President, Frontage Laboratories China, with overall management

Senior Vice President, Frontage Laboratories China, with overall management responsibility for the Frontage China Clinical Laboratory Testing Business Unit and all operational support departments of the Group’s China business.

Graduated from Chu Kochen College, Zhejiang University, majoring in Biomedical Engineering; holds a Master’s degree from the Department of Business Administration, School of Management, Fudan University.

Previously served as Senior Analyst covering the biopharmaceutical industry at Sinolink Securities, and has repeatedly received Best Analyst honors in the pharmaceutical industry from the New Fortune, Crystal Ball, and Golden Bull Awards.

Subsequently joined Dian Diagnostics (300244.SZ), serving successively as Assistant to the Chairman, Group BD & Investment Director, and General Manager of Yunnan Dian Diagnostics.

Joined Teddy Clinical Research Laboratory in 2020, serving successively as Deputy General Manager and General Manager, and has over 10 years of extensive experience in laboratory operations and management.

Read Full Bio
Min Wang

Min Wang

SVP of Frontage China,Operations Support & Clinical &Suzhou Bioanalytics
Min Wang

Min Wang

SVP of Frontage China,Operations Support & Clinical &Suzhou Bioanalytics

Min Wang has more than 10years of industrial experience. Before joined in Frontage, She had been worked as project director and team leader for project managers. The therapeutic areas she had been involved including oncology, endocrinology, cardiology, gastroenterology, rheumatology and immunology studies from phase I till phase III, as well as in Vitro Diagnostic trials. She has chaired many studies passed inspection by CFDI, before the product marked.

Min Wang graduated from North China Coal Medical University, and now is working towards master’s degree of EMBA. Min had been working in Southerncross healthcare group as assistant Nurse in England from 2008 till 2010.

Read Full Bio
Yaodong Huang

Yaodong Huang

SVP of Frontage China Medicinal chemistry
Yaodong Huang

Yaodong Huang

SVP of Frontage China Medicinal chemistry

PhD (UCSB);Acme(8 years); SYNthesis Med Chem (VP of Chemistry); Haoyuan Chemexpress (Executive VP of Chemistry)Joined Acme in 2023

Read Full Bio
Liu Shi

Liu Shi

VP of Frontage China
Liu Shi

Liu Shi

VP of Frontage China

Mrs. Shi has accumulated rich experience in the early stage of drug development activity screening, focusing on the development and validation of various in vitro screening systems related to drug development targets such as GPCR, nuclear receptor, enzymology and high throughput screening.

Mrs. Shi graduated from Beijing Institute of genome research, Chinese Academy of Sciences.

Read Full Bio
Guoqin Niu

Guoqin Niu

VP of Frontage China, CMC China
Guoqin Niu

Guoqin Niu

VP of Frontage China, CMC China

牛国琴博士从事药物制剂研发近二十年,熟悉多种制剂小试、中试放大和工艺验证的研发要求和关键点,熟悉药物制剂开发流程和国内外法规要求,并有多年团队管理经验。

加入方达之前,牛博士先后就职于上海医药、上海创诺、复星星泰和济川药业等。期间负责创新药CMC、改良型新药和仿制药研发、项目管理和团队管理等,主持的项目先后获得20+生产批件。

牛博士本科毕业于原上海医科大学(现复旦大学),获得药学学士学位;博士毕业于复旦大学药学院,获得药剂学博士学位;在美国佛罗里达大学(UF)接受过4年博士后培训。牛博士是上海药学会药剂学专委会委员、中国颗粒学会药物制剂与粒子设计委员会委员。

Read Full Bio
Luke Zhang, MS, MD

Luke Zhang, MS, MD

Vice President / Facility Director of Frontage China Safety Assessment Center (Suzhou)
Luke Zhang, MS, MD

Luke Zhang, MS, MD

Vice President / Facility Director of Frontage China Safety Assessment Center (Suzhou)

Vice President / Facility Director of Frontage China Safety Assessment Center (Suzhou), primarily responsible for drug safety evaluation services at the preclinical safety assessment center in China (Suzhou).

Mr. Zhang has long been engaged in molecular pathology, oncology, toxicologic pathology research, new drug development research, and toxicology evaluation. His experience encompasses 16 years of clinical and basic biomedical research and teaching, as well as 20 years of new drug development, preclinical in vivo and in vitro drug metabolism, pharmacology, and toxicology research. He is an expert in the application development and safety evaluation of biologics (stem cells, vaccines, antibodies, and ADCs), small molecule drugs, and specialty medical devices. He has accumulated extensive experience in animal model development and application, particularly in the use of minipigs in drug safety evaluation. In the area of drug safety assessment, he has overseen or managed the design, conduct, and comprehensive evaluation of more than 2,000 studies, including projects governed by US FDA, OECD, EMEA, NMPA CDE GLP regulations, and ISO standards.

Prior to joining Frontage, Mr. Zhang served as Director of Toxicology and Chief Scientist at Altasciences in the United States, and as Deputy Facility Director and Senior Director of Toxicology (International Business) at Joinn Laboratories (Suzhou). During these tenures, he was primarily responsible for facility and/or departmental management and scientific support. Internally, he formulated and implemented continuous development plans, led organizational restructuring and orderly expansion of departments, optimized essential laboratory procedures, systems, and workflows, and guided new research directions and technologies. Externally, he supported international business development by providing multidimensional scientific, technical, and managerial support, with studies spanning more than 15 countries worldwide.

Mr. Zhang graduated from Guangdong Medical University, where he earned his Bachelor of Medicine degree and Master of Science degree in Pathology. He completed his post-doctoral fellowship training at Harvard Medical School in the United States.

Read Full Bio
Dr. Jin Qian

Dr. Jin Qian

Vice President, has overall responsibility for the Medical/Translational Medicine Department, the Pathology platform, and CDx operations.
Dr. Jin Qian

Dr. Jin Qian

Vice President, has overall responsibility for the Medical/Translational Medicine Department, the Pathology platform, and CDx operations.

Graduated from the Department of Pathology/BMedical Sciences at Fudan University Shanghai Medical College. Held roles including Engineer, Research Management Specialist, Application Engineer, National Training Manager, and Senior Medical Advisor at multinational organizations such as Carl Zeiss Optical Instruments (Shanghai) International Trading Co., Ltd., Dako Medical Device Technical Services (Shanghai) Co., Ltd., and AstraZeneca China, gaining cross-functional expertise in medical technology and pharmaceutical operations. Joined Teddy Clinical Research Laboratory in 2017, leading the development of pathological technology, central laboratory, and translational medicine platforms, with extensive experience in advanced pathological techniques and centralized pathology services for clinical research.

Read Full Bio